World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
86
Citations
36526
World Ranking
13914
National Ranking
7061

Christine Chevreau publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Christine Chevreau sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 512 publications — 60th percentile

60% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Christine Chevreau D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Christine Chevreau sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 86 D-Index — 31st percentile

31% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Christine Chevreau is affiliated with DuPont in the United States. Their research primarily focuses on medicine, with significant contributions across several subfields including pulmonary and respiratory medicine, oncology, surgery, rheumatology, and pathology and forensic medicine.

The scientist has published an extensive number of papers, with the main fields of study encompassing:

  • Medicine

They have worked extensively on topics related to cancer and related treatments. The main areas of research interest include:

  • Sarcoma Diagnosis and Treatment
  • Renal cell carcinoma treatment
  • Cancer Immunotherapy and Biomarkers
  • Vascular Tumors and Angiosarcomas
  • Cancer Genomics and Diagnostics
  • Bladder and Urothelial Cancer Treatments
  • Cardiac tumors and thrombi

Christine Chevreau's work has appeared in a number of frequently featured publication venues such as:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • European Journal of Cancer
  • The Lancet Oncology
  • Cancers

They have collaborated regularly with other researchers, including:

  • Jean-Yves Blay
  • Emmanuelle Bompas
  • Nicolas Penel
  • Sophie Piperno-Neumann
  • Florence Duffaud

Among the recent papers associated with the broader research themes of this scientist are:

  • Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma, 2021, New England Journal of Medicine
  • Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial, 2020, The Lancet Oncology
  • Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial, 2020, Cancer
  • Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial, 2020, The Lancet Oncology
  • Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial, 2022, The Lancet Oncology

Best Publications

  • Sorafenib in advanced clear-cell renal-cell carcinoma.

    Bernard Escudier;Tim Eisen;Walter M. Stadler;Cezary Szczylik

  • Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

    Bernard Escudier;Anna Pluzanska;Piotr Koralewski;Alain Ravaud

  • Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

    Bernard Escudier;Tim Eisen;Walter M. Stadler;Cezary Szczylik

  • Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma

    Sylvie Negrier;Bernard Escudier;Christine Lasset;Jean-Yves Douillard

  • Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience

    Andrés J M Ferreri;Jean Yves Blay;Michele Reni;Felice Pasini

  • Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.

    Arnaud Méjean;Alain Ravaud;Simon Thezenas;Sandra Colas

  • Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study

    Nicolas Penel;Binh Nguyen Bui;Jacques-Olivier Bay;Didier Cupissol

  • Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987

    Joaquim Bellmunt;Hans von der Maase;Graham M. Mead;Iwona Skoneczna

  • Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.

    Toni K. Choueiri;Piotr Tomczak;Se Hoon Park;Balaji Venugopal

  • High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series.

    J Y Blay;T Conroy;C Chevreau;A Thyss

  • Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    Thomas Powles;Michiel S van der Heijden;Daniel Castellano;Matthew D Galsky

  • Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d’Immunothérapie

    S. Négrier;B. Escudier;F. Gomez;J.-Y. Douillard

  • Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.

    Maud Toulmonde;Nicolas Penel;Julien Adam;Julien Adam;Christine Chevreau

  • Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study.

    M de Forni;Myriam Malet-Martino;P Jaillais;R Shubinski

  • Prediction of Carboplatin Clearance From Standard Morphological and Biological Patient Characteristics

    Etienne Chatelut;Pierre Canal;Valérie Brunner;Christine Chevreau

  • Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial

    Axel Le Cesne;Isabelle Ray-Coquard;Binh Nguyen Bui;Antoine Adenis

  • Improved survival using specialized multidisciplinary board in sarcoma patients.

    J.-Y. Blay;P. Soibinet;N. Penel;E. Bompas

  • Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial

    Sylvie Négrier;Gwenaëlle Gravis;David Pérol;Christine Chevreau

  • Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.

    Florence Duffaud;Olivier Mir;Pascaline Boudou-Rouquette;Sophie Piperno-Neumann

  • Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up.

    N. Penel;A. Le Cesne;B.N. Bui;D. Perol

Frequent Co-Authors

Jean-Yves Blay
Jean-Yves Blay Claude Bernard University Lyon 1
François Bertucci
François Bertucci Aix-Marseille University
Axel Le Cesne
Axel Le Cesne Institut Gustave Roussy
Bernard Escudier
Bernard Escudier Institut Gustave Roussy
Antoine Italiano
Antoine Italiano University of Bordeaux
Isabelle Ray-Coquard
Isabelle Ray-Coquard Claude Bernard University Lyon 1
Alain Ravaud
Alain Ravaud University of Bordeaux
Stéphane Oudard
Stéphane Oudard Hôpital Européen Georges-Pompidou
Laurence Albiges
Laurence Albiges Institut Gustave Roussy
Karim Fizazi
Karim Fizazi University of Paris-Saclay

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

As you consider studying Medicine in the USA, it’s valuable to explore related online degrees and alternative career pathways that support the healthcare ecosystem. These flexible academic options can help you start or advance your medical career based on your interests and goals.

For those looking to become nurses quickly and without the stress of strict admission exams, you can find an lpn program no entrance exam. This can be a practical entry point into nursing, offering a more streamlined admission process.

If you’re interested in the administrative side of healthcare, accredited online health administration programs allow you to develop leadership skills and pursue roles in management, policy, and organization within medical settings.

Already an RN? Accelerate your career with rn to fnp bridge programs, which enable registered nurses to earn their advanced practice credentials and become Family Nurse Practitioners in less time.

Those passionate about wellness and preventive care can earn a bachelor's in nutrition online, opening doors to careers in dietetics, research, and health education.

These related online degrees offer flexible, accessible ways to enter or grow within the healthcare field, catering to a wide range of interests and career ambitions.

Best Scientists Citing Christine Chevreau

Trending Scientists

Recently Published Articles